One trial is evaluating the investigational agent alone in patients with first recurrence of glioma while the second trial is evaluating<unk>  (Vitespen) in combination with Temozolomide, a common chemotherapy, in patients that are newly diagnosed with brain cancer. A first phase I clinical trial in glioma extended median survival of the group of patients, which was diagnosed with multiple recurrencies of glioma, to over 10 months.
Oncophage
Lentivirus
Oncovirus
Oncolytic virus
Passenger virus
Pandemrix
Oncolytic adenovirus
Arbovirus